Developer docs
API playgroundTry for free, no card

Search company profiles

Cerca Biotech

Full company profile

uuid002c2et

Namestring
Cerca Biotech
Legal namestring
Cerca Biotech GmbH
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Cerca Biotech GmbH is a Berlin-headquartered European subsidiary of Shuwen Biotech, a molecular and point-of-care diagnostics organization based in China. Founded around 2021, the company manufactures and markets in-vitro diagnostic (IVD) products focused on women's health, specifically molecular subtyping of breast cancer. The firm operates with a small team of 1-10 employees.

The company's core offering is MammaTyper®, a standardized RT-qPCR (reverse transcription quantitative polymerase chain reaction) IVD assay that quantifies four key breast cancer biomarkers — ERBB2 (HER2), ESR1 (estrogen receptor), PGR (progesterone receptor), and MKI67 (Ki-67) — to determine molecular subtypes including Luminal A-like, Luminal B-like (HER2 negative), Luminal B-like (HER2 positive), HER2-positive (non-luminal), and triple-negative. The test uses a proprietary 40-ΔΔCq algorithm combined with multiplex control genes to deliver results with documented concordance of 95% for HER2 and 94.7% for ER against IHC/FISH reference standards. A complementary product, RNXtract®, is a magnetic-bead IVD kit for extracting and purifying total RNA from formalin-fixed, paraffin-embedded (FFPE) samples, enabling the upstream sample preparation required for the MammaTyper workflow. The company also offers the MammaTyper Report Generator, a web-based platform accepting data from eight real-time PCR instrument families (Roche LightCycler, Bio-Rad CFX96, Agilent Mx3000P, ThermoFisher, etc.) to calculate molecular subtypes using the proprietary algorithm.

Commercially, Cerca Biotech sells its IVD kits through a four-region distributor network covering Asia Pacific, EMEA, Latin America, and North America, with no direct sales force. Pricing is not publicly disclosed. The company targets clinical pathology laboratories and oncology healthcare providers, addressing pain points around the reproducibility limitations of immunohistochemistry (IHC), accurate HER2-low classification for emerging antibody-drug conjugate therapies, and identification of patients unlikely to benefit from chemotherapy. Products carry CE marking for the European market, and the company operates an ISO 13485 quality management system with active IVDR readiness preparation. Marketing is concentrated on clinical evidence generation — peer-reviewed publications, KOL engagement at St Gallen and SABCS conferences, white papers, and LinkedIn newsletter content — rather than broad promotional spend.

Short descriptiontext

Cerca Biotech GmbH is a Berlin-based European subsidiary of Shuwen Biotech that markets RT-qPCR-based IVD tests (MammaTyper® for breast cancer subtyping and RNXtract® for FFPE RNA extraction) to clinical pathology laboratories and oncology providers globally through a four-region distributor network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBristol, United Kingdom
HQ citystring
Bristol
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, breast cancer subtyping, RT-qPCR assays, RNA extraction kits, in vitro diagnostics
Industry4 codes
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1MammaTyper® Diagnostic Test Kits
TypeOne Time License
Description

Sale of IVD diagnostic test kits for breast cancer molecular subtyping to clinical laboratories and healthcare institutions through distributor network.

cercabiotech.com
2RNXtract® RNA Extraction Products
TypeOne Time License
Description

Sale of FFPE RNA extraction kits for routine clinical laboratory use.

cercabiotech.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MammaTyper®
Description

RT-qPCR assay for breast cancer subtyping, quantifying four key biomarkers: ERBB2 (HER2), ESR1 (estrogen receptor 1), PGR (progesterone receptor), and MKI67 (Ki-67).

cercabiotech.com
+1 more record
Core offering1 text field

Cerca Biotech manufactures and markets IVD molecular diagnostic products for breast cancer. Its flagship product, MammaTyper®, is an RT-qPCR assay that quantifies four biomarkers (ER, PR, HER2, Ki-67) to determine molecular breast cancer subtypes. The complementary RNXtract® kit extracts RNA from FFPE samples using magnetic beads, and the MammaTyper® Report Generator is a web-based software tool for calculating subtypes from multiple qPCR instruments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 95% concordance for HER2 testing vs FISH reference standard, meeting ASCO-CAP guidelines requirement
+3 more records
Product overview1 text field

Cerca Biotech is a molecular diagnostics company offering two main IVD products. MammaTyper is a standardized RT-qPCR assay for quantifying four breast cancer biomarkers (ER, PR, HER2, Ki-67) to support molecular subtyping and treatment decisions. RNXtract is an RNA extraction kit designed for routine clinical use with FFPE samples. The company also provides the MammaTyper Report Generator, a companion web platform that accepts data from multiple real-time PCR instruments to calculate and report molecular subtypes. The portfolio enables accurate, reproducible breast cancer classification to guide targeted therapy selection.

Product and service3 records
1MammaTyper®
CategoryMolecular diagnostics — breast cancer subtyping assay
Description

An IVD RT-qPCR (reverse transcription quantitative real-time PCR) assay for molecular subtyping of breast cancer. Quantifies four key biomarkers—ER (ESR1), PR (PGR), HER2 (ERBB2), and Ki-67 (MKI67)—to determine breast cancer subtypes including Luminal A-like, Luminal B-like (HER2 negative), Luminal B-like (HER2 positive), HER2 positive (non-luminal), and Triple negative. Designed for clinical pathology laboratories and oncology healthcare providers for treatment decision support.

2RNXtract®
CategoryMolecular diagnostics — sample preparation / RNA extraction
Description

An IVD product designed for routine clinical use to extract and purify total RNA from formalin-fixed, paraffin-embedded (FFPE) samples using magnetic beads. Provides a fast, reliable method for obtaining high-quality, amplifiable RNA for subsequent molecular biology techniques including RT-qPCR testing, intended for clinical pathology laboratories.

3MammaTyper® Report Generator
CategoryCompanion software / data analysis platform
Description

Web-based software tool for generating MammaTyper® test reports. Accepts data import from various real-time PCR instruments including LightCycler480 II, cobas480, SLAN-96P, CFX96, AriaDx, MX3000P, ABI7500, and Versant kPCR systems. Calculates molecular subtypes using the 40-ΔΔCq algorithm with defined cut-offs for ERBB2, ESR1, PGR, and MKI67 biomarkers, and displays CE marking.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Shuwen Biotech is the parent company of Cerca Biotech. Cerca Biotech GmbH, based in Berlin, is the European subsidiary of Shuwen Biotech, described as a highly reputable and innovative molecular and point of care diagnostics organization. Both companies are passionate about healthcare and working to create world leading innovations in oncology and women's health diagnostics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Originally developed the Prosigna/PAM50 test using nCounter gene expression technology for breast cancer subtyping. Directly comparable molecular diagnostics peer in breast cancer classification.

TypeBroad incumbent
Description

Operates a broad IVD and molecular diagnostics portfolio including the cobas and LightCycler qPCR platforms that MammaTyper is compatible with. Adjacent incumbent that could either partner with or squeeze out smaller PCR-based test developers.

TypeOthers
Description

Supplies reagents, proteins, and molecular biology tools used in RT-qPCR and biomarker workflows. Comparable as an enabling life science tools vendor that participates in the same molecular diagnostics value chain.

TypeDirect peer
Description

Provider of MammaPrint and BluePrint tests for breast cancer recurrence risk and molecular subtyping. Direct competitor in the same breast cancer molecular diagnostics category.

TypeBroad incumbent
Description

Women's health diagnostics leader with strong presence in breast cancer screening and cytology. Comparable focus on women's health oncology, though more entrenched in imaging/cytology than molecular subtyping.

TypeBroad incumbent
Description

Provider of sample-prep and molecular diagnostic technologies used in PCR workflows, including companion diagnostic development. Comparable business model in IVD molecular testing infrastructure and reagents.

TypeDirect peer
Description

Molecular diagnostics company that acquired the Prosigna/PAM50 breast cancer subtyping test. Competes directly with MammaTyper in the same clinical decision-support category for breast cancer.

TypeDirect peer
Description

Developer of the Breast Cancer Index (BCI), a molecular test predicting recurrence risk and benefit of extended endocrine therapy in breast cancer. Comparable niche player in breast cancer prognostic diagnostics.

TypeDirect peer
Description

Developer of Oncotype DX Breast Recurrence Score, the leading multigene breast cancer prognostic test. Direct competitor to MammaTyper in guiding chemotherapy and endocrine therapy decisions in breast cancer.

TypeBroad incumbent
Description

Acquired Oncotype DX through its Thrive and Genomic Health transactions and operates a broad oncology diagnostics platform. Competes in breast cancer subtyping as part of a much larger molecular diagnostics portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cerca Biotech

Molecular Diagnosticscercabiotech.com

Cerca Biotech GmbH is a Berlin-based European subsidiary of Shuwen Biotech that markets RT-qPCR-based IVD tests (MammaTyper® for breast cancer subtyping and RNXtract® for FFPE RNA extraction) to clinical pathology laboratories and oncology providers globally through a four-region distributor network.

What Cerca Biotech does

Cerca Biotech GmbH is a Berlin-headquartered European subsidiary of Shuwen Biotech, a molecular and point-of-care diagnostics organization based in China. Founded around 2021, the company manufactures and markets in-vitro diagnostic (IVD) products focused on women's health, specifically molecular subtyping of breast cancer. The firm operates with a small team of 1-10 employees.

The company's core offering is MammaTyper®, a standardized RT-qPCR (reverse transcription quantitative polymerase chain reaction) IVD assay that quantifies four key breast cancer biomarkers — ERBB2 (HER2), ESR1 (estrogen receptor), PGR (progesterone receptor), and MKI67 (Ki-67) — to determine molecular subtypes including Luminal A-like, Luminal B-like (HER2 negative), Luminal B-like (HER2 positive), HER2-positive (non-luminal), and triple-negative. The test uses a proprietary 40-ΔΔCq algorithm combined with multiplex control genes to deliver results with documented concordance of 95% for HER2 and 94.7% for ER against IHC/FISH reference standards. A complementary product, RNXtract®, is a magnetic-bead IVD kit for extracting and purifying total RNA from formalin-fixed, paraffin-embedded (FFPE) samples, enabling the upstream sample preparation required for the MammaTyper workflow. The company also offers the MammaTyper Report Generator, a web-based platform accepting data from eight real-time PCR instrument families (Roche LightCycler, Bio-Rad CFX96, Agilent Mx3000P, ThermoFisher, etc.) to calculate molecular subtypes using the proprietary algorithm.

Commercially, Cerca Biotech sells its IVD kits through a four-region distributor network covering Asia Pacific, EMEA, Latin America, and North America, with no direct sales force. Pricing is not publicly disclosed. The company targets clinical pathology laboratories and oncology healthcare providers, addressing pain points around the reproducibility limitations of immunohistochemistry (IHC), accurate HER2-low classification for emerging antibody-drug conjugate therapies, and identification of patients unlikely to benefit from chemotherapy. Products carry CE marking for the European market, and the company operates an ISO 13485 quality management system with active IVDR readiness preparation. Marketing is concentrated on clinical evidence generation — peer-reviewed publications, KOL engagement at St Gallen and SABCS conferences, white papers, and LinkedIn newsletter content — rather than broad promotional spend.

Cerca Biotech firmographics

Firmographics
Name
Cerca Biotech
Legal name
Cerca Biotech GmbH
Website
https://cercabiotech.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Cerca Biotech GmbH is a Berlin-based European subsidiary of Shuwen Biotech that markets RT-qPCR-based IVD tests (MammaTyper® for breast cancer subtyping and RNXtract® for FFPE RNA extraction) to clinical pathology laboratories and oncology providers globally through a four-region distributor network.
Ownership category
akta.pro rank

Cerca Biotech industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAF
Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Molecular diagnostics
  • Breast cancer subtyping
  • RT-qPCR assays
  • RNA extraction kits
  • In vitro diagnostics

Where Cerca Biotech is headquartered

Location

Headquarters

HQ city
Bristol
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Cerca Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. MammaTyper® Diagnostic Test Kits: Sale of IVD diagnostic test kits for breast cancer molecular subtyping to clinical laboratories and healthcare institutions through distributor network.
  2. RNXtract® RNA Extraction Products: Sale of FFPE RNA extraction kits for routine clinical laboratory use.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Cerca Biotech product offering

Product offering

Core offering

Cerca Biotech manufactures and markets IVD molecular diagnostic products for breast cancer. Its flagship product, MammaTyper®, is an RT-qPCR assay that quantifies four biomarkers (ER, PR, HER2, Ki-67) to determine molecular breast cancer subtypes. The complementary RNXtract® kit extracts RNA from FFPE samples using magnetic beads, and the MammaTyper® Report Generator is a web-based software tool for calculating subtypes from multiple qPCR instruments.

Product overview

Cerca Biotech is a molecular diagnostics company offering two main IVD products. MammaTyper is a standardized RT-qPCR assay for quantifying four breast cancer biomarkers (ER, PR, HER2, Ki-67) to support molecular subtyping and treatment decisions. RNXtract is an RNA extraction kit designed for routine clinical use with FFPE samples. The company also provides the MammaTyper Report Generator, a companion web platform that accepts data from multiple real-time PCR instruments to calculate and report molecular subtypes. The portfolio enables accurate, reproducible breast cancer classification to guide targeted therapy selection.

Differentiator

Problem solved

Functional benefit

Brands

  • MammaTyper®: RT-qPCR assay for breast cancer subtyping, quantifying four key biomarkers: ERBB2 (HER2), ESR1 (estrogen receptor 1), PGR (progesterone receptor), and MKI67 (Ki-67).
  • RNXtract®

Products and services

  • MammaTyper® An IVD RT-qPCR (reverse transcription quantitative real-time PCR) assay for molecular subtyping of breast cancer. Quantifies four key biomarkers—ER (ESR1), PR (PGR), HER2 (ERBB2), and Ki-67 (MKI67)—to determine breast cancer subtypes including Luminal A-like, Luminal B-like (HER2 negative), Luminal B-like (HER2 positive), HER2 positive (non-luminal), and Triple negative. Designed for clinical pathology laboratories and oncology healthcare providers for treatment decision support.
  • RNXtract® An IVD product designed for routine clinical use to extract and purify total RNA from formalin-fixed, paraffin-embedded (FFPE) samples using magnetic beads. Provides a fast, reliable method for obtaining high-quality, amplifiable RNA for subsequent molecular biology techniques including RT-qPCR testing, intended for clinical pathology laboratories.
  • MammaTyper® Report Generator Web-based software tool for generating MammaTyper® test reports. Accepts data import from various real-time PCR instruments including LightCycler480 II, cobas480, SLAN-96P, CFX96, AriaDx, MX3000P, ABI7500, and Versant kPCR systems. Calculates molecular subtypes using the 40-ΔΔCq algorithm with defined cut-offs for ERBB2, ESR1, PGR, and MKI67 biomarkers, and displays CE marking.

Quantifiable outcome

  • 95% concordance for HER2 testing vs FISH reference standard, meeting ASCO-CAP guidelines requirement
  • +3 more outcomes

Companies that use Cerca Biotech

Customer profile

Segments3 records

Ideal customer profiles2 records

Cerca Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cerca Biotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Shuwen BiotechcoreStrategic or Co-development PartnerShuwen Biotech is the parent company of Cerca Biotech. Cerca Biotech GmbH, based in Berlin, is the European subsidiary of Shuwen Biotech, described as a highly reputable and innovative molecular and point of care diagnostics organization. Both companies are passionate about healthcare and working to create world leading innovations in oncology and women's health diagnostics.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Cerca Biotech competitors and assessment

Company assessment

Direct peers

  • NanoString Technologies: Originally developed the Prosigna/PAM50 test using nCounter gene expression technology for breast cancer subtyping. Directly comparable molecular diagnostics peer in breast cancer classification.
  • Agendia: Provider of MammaPrint and BluePrint tests for breast cancer recurrence risk and molecular subtyping. Direct competitor in the same breast cancer molecular diagnostics category.
  • Veracyte: Molecular diagnostics company that acquired the Prosigna/PAM50 breast cancer subtyping test. Competes directly with MammaTyper in the same clinical decision-support category for breast cancer.
  • Biotheranostics: Developer of the Breast Cancer Index (BCI), a molecular test predicting recurrence risk and benefit of extended endocrine therapy in breast cancer. Comparable niche player in breast cancer prognostic diagnostics.
  • Myriad Genetics: Developer of Oncotype DX Breast Recurrence Score, the leading multigene breast cancer prognostic test. Direct competitor to MammaTyper in guiding chemotherapy and endocrine therapy decisions in breast cancer.

Broad incumbents

  • Roche Diagnostics: Operates a broad IVD and molecular diagnostics portfolio including the cobas and LightCycler qPCR platforms that MammaTyper is compatible with. Adjacent incumbent that could either partner with or squeeze out smaller PCR-based test developers.
  • Hologic: Women's health diagnostics leader with strong presence in breast cancer screening and cytology. Comparable focus on women's health oncology, though more entrenched in imaging/cytology than molecular subtyping.
  • QIAGEN: Provider of sample-prep and molecular diagnostic technologies used in PCR workflows, including companion diagnostic development. Comparable business model in IVD molecular testing infrastructure and reagents.
  • Exact Sciences: Acquired Oncotype DX through its Thrive and Genomic Health transactions and operates a broad oncology diagnostics platform. Competes in breast cancer subtyping as part of a much larger molecular diagnostics portfolio.

Others

  • Bio-Techne: Supplies reagents, proteins, and molecular biology tools used in RT-qPCR and biomarker workflows. Comparable as an enabling life science tools vendor that participates in the same molecular diagnostics value chain.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Cerca Biotech social profiles

Digital presence

Cerca Biotech compliance and trust

Trust signal

Compliance3 records

Cerca Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cerca Biotech leadership team

Management profile

Number of profiles

Profiles6 records

Cerca Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cerca Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cerca Biotech

What does Cerca Biotech do?

Cerca Biotech manufactures and markets IVD molecular diagnostic products for breast cancer. Its flagship product, MammaTyper®, is an RT-qPCR assay that quantifies four biomarkers (ER, PR, HER2, Ki-67) to determine molecular breast cancer subtypes. The complementary RNXtract® kit extracts RNA from FFPE samples using magnetic beads, and the MammaTyper® Report Generator is a web-based software tool for calculating subtypes from multiple qPCR instruments.

Is Cerca Biotech a public or private company?

Cerca Biotech is a private company. It is classified as corporate owned and is currently operating.

When was Cerca Biotech founded?

Cerca Biotech was founded in 2021. It employs 1 to 10 people.

Where is Cerca Biotech based?

Cerca Biotech is headquartered in Bristol, United Kingdom, in the Europe region.

How does Cerca Biotech make money?

Two revenue lines are on record. MammaTyper® Diagnostic Test Kits are the primary driver. The others are RNXtract® RNA Extraction Products.

Who are Cerca Biotech's main competitors?

Direct peers on record are NanoString Technologies, Agendia, Veracyte, Biotheranostics and Myriad Genetics. Broad incumbents are Roche Diagnostics, Hologic, QIAGEN and Exact Sciences. Bio-Techne is listed as an others.

Does Cerca Biotech have an API?

No public API is recorded for Cerca Biotech.

What industry is Cerca Biotech in?

Cerca Biotech's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireSCORE Study Results of MammaTyper® LRP Model in HR+/HER2− Breast Cancer Presented at ECP 2026Cerca Biotech presented SCORE study results at ECP 2026, showing MammaTyper LRP identifies HR+/HER2− breast cancer patients with Oncotype DX RS ≤25. The model has a 95% positive predictive value for low recurrence risk, supporting its use as a low-cost pre-screen.EIN PresswireMammaTyper® LRP Score Demonstrates Prognostic Value in Early Luminal Breast CancerA study of 402 early-stage luminal breast cancer patients found the MammaTyper LRP score an independent prognostic factor, with low-risk patients achieving 96.2% distant disease-free survival versus 87.0% in high-risk patients. The score may help identify patients with limited benefit from adjuvant chemotherapy.EIN PresswireCerca Biotech Releases New White Paper on Ki-67 Testing in Breast CancerCerca Biotech published a white paper on MammaTyper's Ki-67 testing, citing inter- and intra-laboratory reproducibility with kappa coefficients of 0.90–1.00. The paper claims the assay removes subjectivity from IHC, improving clinical concordance and reducing retesting rates.EIN PresswireShuwen Biotech Receives Exclusive Patent License from Cologne UniversityShuwen Biotech and its European subsidiary Cerca Biotech signed an exclusive patent license with the University Hospital of Cologne for theranostic biomarkers and FGFR inhibitors. The agreement covers major markets, and the company plans to develop a therapeutic program with a companion diagnostic test.EIN PresswireStudy Presented at SABCS 2025 Demonstrates Identification of Low Risk Luminal Breast Cancer Patients Using MammaTyper®A study presented at the San Antonio Breast Cancer Symposium 2025 demonstrated that MammaTyper\®, a molecular diagnostic test developed by Cerca Biotech GmbH, accurately identifies low-risk ER+/HER2- breast cancer patients who had significantly better 9-year distant disease-free survival and did not benefit from adjuvant chemotherapy. The research, led by Professor Ling Xu of Peking University First Hospital, further validated the MammaTyper® LRP score as a low-cost and locally available pre-screen for the Oncotype Dx Breast Recurrence Score® test. Cerca Biotech GmbH highlighted the clinical benefits of MammaTyper® in supporting precision medicine in breast cancer.EIN PresswireWhite Paper Published on HER2-Low Breast Cancer: the Case for Molecular DiagnosticsGerman diagnostics company Cerca Biotech announced the publication of a white paper highlighting the role of molecular diagnostics in improving HER2-low breast cancer classification. The white paper focuses on the company's MammaTyper® test, a standardized RT-qPCR assay for quantifying four key breast cancer biomarkers to support treatment decisions. The publication coincides with Breast Cancer Awareness Month and emphasizes how quantitative molecular tools can resolve ambiguity in borderline HER2 expression cases.ShuwendxSHUWEN BIOTECH – 数问生物Cerca Biotech presented study results at SABCS 2025 demonstrating that MammaTyper® can identify low-risk luminal breast cancer patients who do not benefit from adjuvant chemotherapy. Additionally, the company presented prospective clinical study results for CercaTest RED™ at the Asia Pacific Congress in Maternal Fetal Medicine 2025 in Osaka, Japan.